MétaCan
Menu
Back to cohort
Record W4393087180 · doi:10.1158/1538-7445.am2024-3299

Abstract 3299: Harnessing PIKfyve as a therapeutic vulnerability in neuroendocrine prostate cancer

2024· article· en· W4393087180 on OpenAlexaff
Yang Zheng, Kyle Garcia Rogers, Arya Gopal Kamat, Sarah Nicole Yee, Rahul Mannan, Xia Jiang, Rowena Kannaiyan, Xuhong Cao, Yuzhuo Wang, Yuanyuan Qiao, Arul M. Chinnaiyan

Bibliographic record

VenueCancer Research · 2024
Typearticle
Languageen
FieldMedicine
TopicAdvanced Breast Cancer Therapies
Canadian institutionsUniversity of British Columbia
Fundersnot available
KeywordsProstate cancerCancerMedicineVulnerability (computing)ProstateOncologyInternal medicineComputer science

Abstract

fetched live from OpenAlex

Abstract Neuroendocrine prostate cancer (NEPC) represents an aggressive subtype characterized by the independence on androgen receptor (AR) signaling and the acquisition of neuroendocrine features. Despite its rarity among prostate cancer cases, NEPC carries a particularly poor prognosis with limited treatment options. Our prior investigation demonstrated the heightened efficacy of targeting PIKfyve with ESK981 in AR- prostate cancer models, prompting further exploration. In this study, we expanded our investigation to assess the efficacy of ESK981 monotherapy across five NEPC models, encompassing one cell line xenograft and four patient-derived xenografts (PDXs). Our findings revealed consistent tumor inhibition and notable regression in select models. Comparative analysis highlighted the superior effectiveness of ESK981 in NEPC compared to AR+ prostate cancer, as evident through percent tumor growth inhibition (%TGI) assessments. Early evaluations post five days of treatment (PD5) unveiled that PIKfyve inhibition induced apoptotic cell death specifically in NEPC models, confirmed through immunoblotting and TUNEL staining in a time-dependent manner. Intriguingly, PD5 TUNEL positivity correlated with endpoint %TGI, suggesting its potential as a predictor for long-term efficacy. To further delineate the role of PIKfyve in NEPC, we successfully established two novel ex vivo NEPC cell lines from these PDXs, overcoming the constraint of limited publicly accessible NEPC cell lines, and confirmed their NEPC characteristics. Employing a doxycycline-inducible PIKfyve knockdown system in these cells demonstrated significant tumor inhibition in xenograft models, albeit with a lower %TGI compared to ESK981 monotherapy. In conclusion, our results illuminate the preferential cytotoxicity of PIKfyve inhibition in NEPC tumors compared to AR+ prostate cancer, advocating PIKfyve as a compelling therapeutic target. This study provides a strong rationale for advancing ESK981 into clinical trials for NEPC patients, underscoring its potential in addressing this challenging malignancy. Citation Format: Yang Zheng, Kyle Garcia Rogers, Arya Gopal Kamat, Sarah Nicole Yee, Rahul Mannan, Xia Jiang, Rowena Kannaiyan, Xuhong Cao, Yuzhuo Wang, Yuanyuan Qiao, Arul M. Chinnaiyan. Harnessing PIKfyve as a therapeutic vulnerability in neuroendocrine prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 3299.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesInsufficient payload (model declined to judge)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Other design · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.782
Threshold uncertainty score0.998

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0010.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0010.002
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.002
Insufficient payload (model declined to judge)0.0030.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.097
GPT teacher head0.478
Teacher spread0.381 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designOther design
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2024
Admission routes1
Has abstractyes

Explore more

Same venueCancer ResearchSame topicAdvanced Breast Cancer TherapiesFrench-language works237,207